• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Medtronic plc.

    5/28/25 5:30:45 PM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $MDT alert in real time by email
    SD 1 formsd-2024conflictminerals.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    FORM SD
    Specialized Disclosure Report
     
     
    Medtronic plc
    (Exact name of Registrant as Specified in its Charter)
     
     
     
    Ireland 1-36820 98-1183488
    (State or other jurisdiction
    of incorporation)
     (Commission
    File Number)
     (IRS Employer
    Identification No.)
     
    Building Two, Parkmore Business Park West
    Galway, Ireland
     n/a
    (Address of principal executive offices) (Zip Code)

     
    Thierry Piéton 763-514-4000
    (Name and telephone number, including area code, of the person to contact in connection with this report.)
     
     
    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:
     
    xRule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.




    INFORMATION TO BE INCLUDED IN THE REPORT

    Section 1 - Conflict Minerals Disclosure


    Item 1.01 Conflict Minerals Disclosure and Report
    This Form SD of Medtronic plc (the “Company”) is filed pursuant to Rule 13p-1 (the “Rule”) promulgated under the Securities Exchange Act of 1934, as amended, for the reporting period from January 1, 2024 to December 31, 2024
    A copy of Company’s Conflict Minerals Report is provided as Exhibit 1.01 hereto and details the due diligence measures undertaken during the reporting period by the Company on a consolidated basis. A copy of the Conflict Minerals Report is also publicly available through the Company’s website by clicking the SEC Filings link under the Financials drop-down at www.investorrelations.medtronic.com.
    Item 1.02 Exhibit

    The Company has filed, as an exhibit to this Form SD, the Conflict Minerals Report of the Company required by Item 1.01.

    Section 2 - Exhibits


    Item 2.01 Exhibits

    The following exhibit is filed as part of this report:

    Exhibit 1.01 - Conflict Minerals Report of the Company




    SIGNATURES
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.
     
    Medtronic plc
    Date: May 28, 2025By/s/ Thierry Piéton
    Thierry Piéton
    Executive Vice President and Chief Financial Officer




    EXHIBIT INDEX
    Medtronic plc
    Form SD
     
    Exhibit No.  Description
    1.01
      
    Conflict Minerals Report of the Company

    Get the next $MDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MDT

    DatePrice TargetRatingAnalyst
    6/16/2025$110.00Outperform
    Leerink Partners
    3/4/2025$92.00 → $107.00Neutral → Buy
    Citigroup
    10/10/2024$98.00 → $105.00Sector Perform → Outperform
    RBC Capital Mkts
    8/21/2024$92.00 → $94.00Perform
    Oppenheimer
    8/15/2024$76.00 → $90.00Sell → Neutral
    UBS
    8/14/2024$100.00 → $85.00Buy → Hold
    Stifel
    5/30/2024$83.00Sell
    Goldman
    7/19/2023$90.00Neutral
    Robert W. Baird
    More analyst ratings